Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review

A cystic fibrosis (CF) transmembrane conductor regulator (CFTR) gene modulating triple therapy combining elexacaftor-tezacaftor-ivacaftor (Trikafta) has been recently discovered. Its approval by the Food and Drug Administration (FDA) in 2019 has expanded the target therapy group to individuals aged twelve and up with at least one Phe508del (phenylalanine 508 deletion) mutation in the CFTR gene. This systematic review aims to assess this combination therapy's safety and efficacy. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, an in-depth search was performed. The search was done by utilizing databases such as PubMed Central (PMC), Google Scholar, and Science Direct for articles related to this topic. Studies published in the last five years in the English language were chosen preliminarily. Further eligibility criteria and quality assessment tools were employed to assess the risk of bias and finalize ten articles to be used in this review. The chosen articles constituted four randomized control trials (RCTs), four systematic reviews, and two narrative reviews. The last date for data collection was April 24, 2022. Based on the findings of this review, we concluded that by combining three CFTR modulators, this therapy had outperformed all the currently available medications in terms of improving pulmonary function, reducing exacerbations, and enhancing the quality of life of CF patients. In clinical trials, headache and rash were the most common side effects, and laboratory testing to assess liver function is suggested. Long-term safety and effectiveness must be confirmed by the continued review of real-life patient data. Studies done on triple therapy thus far have been promising. Unfortunately, a small proportion of the CF population remains ineligible for any form of CFTR modulator therapy owing to their type of genetic mutation, and this provides ground for further research in this field.

[1]  R. Robey,et al.  Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy , 2021, Breathe.

[2]  Rutger M van den Bor,et al.  Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators , 2021, Journal of personalized medicine.

[3]  L. Hoffman,et al.  Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial , 2021, American journal of respiratory and critical care medicine.

[4]  V. Fainardi,et al.  State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy , 2021, Pharmaceuticals.

[5]  J. Taylor-Cousar,et al.  Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world – opportunities and challenges , 2021, Current opinion in pulmonary medicine.

[6]  Jude ElSaygh,et al.  A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy , 2021, Cureus.

[7]  G. Castaldo,et al.  Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype , 2021, Antibiotics.

[8]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[9]  R. Gibson,et al.  A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele , 2021, American journal of respiratory and critical care medicine.

[10]  V. Miller,et al.  Novel reaction to new cystic fibrosis medication Trikafta , 2020, Clinical case reports.

[11]  B. Quon,et al.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review , 2020, Journal of clinical medicine.

[12]  C. Castellani,et al.  From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis , 2020, International journal of molecular sciences.

[13]  Michelle Condren,et al.  Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. , 2020, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[14]  J. Taylor-Cousar,et al.  Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease , 2020, European Respiratory Review.

[15]  C. Bear.  A Therapy for Most with Cystic Fibrosis , 2020, Cell.

[16]  S. Rowe,et al.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. , 2019, American journal of respiratory and critical care medicine.

[17]  Jeong-Soo Hong,et al.  Cystic fibrosis precision therapeutics: Emerging considerations , 2019, Pediatric pulmonology.

[18]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[19]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[20]  J. Engelhardt,et al.  Advances In Gene Therapy For Cystic Fibrosis Lung Disease. , 2019, Human molecular genetics.

[21]  D. Waltz,et al.  Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles , 2019, ERJ Open Research.

[22]  C. Goss,et al.  The future of cystic fibrosis care: a global perspective. , 2020, The Lancet. Respiratory medicine.

[23]  M. Papaluca,et al.  A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators , 2018, European Respiratory Review.

[24]  S. Nevitt,et al.  Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. , 2014, The Cochrane database of systematic reviews.

[25]  Susanne Naehrig,et al.  Cystic Fibrosis. , 2017, Deutsches Ärzteblatt International.

[26]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.